Literature DB >> 29273940

Investigation of Clostridium difficile ribotypes in symptomatic patients of a German pediatric oncology center.

Arne Simon1,2, Markus Mock3, Norbert Graf4, Lutz von Müller3.   

Abstract

In a German pediatric oncology unit, the attending physicians diagnosed 27 cases of Clostridium difficile-associated disease (CDI) from January 01, 2010 to October 31, 2013. This refers to a CDI incidence density of 2.0/1000 inpatient days. According to the hospital hygiene standard, symptomatic patients with CDI were kept in contact isolation. Most patients (median age 8.2 years) suffered from acute lymphoblastic leukemia; 88.9% were treated with broad-spectrum antibiotics during the preceding 4 weeks. 29.6% received intravenous morphine/metamizole and parenteral nutrition due to severe chemotherapy-induced mucositis. None of the patients experienced severe complications such as lower gastrointestinal tract bleeding, sepsis, or toxic megacolon. Genotyping of the isolates derived from symptomatic patients revealed many different ribotypes without detection of the hypervirulent 027 strain and did not point at hospital transmission as an important promoter of CDI in our unit.
CONCLUSION: Under strict standard hygiene and contact isolation for symptomatic patients, genotyping of clinical isolates revealed that in pediatric cancer patients, CDI is not necessarily based on nosocomial transmission. The rate of CDI-related severe complications was low. What is Known: • Pediatric cancer patients face an increased risk of Clostridium difficile-associated disease due to immunosuppression, cancer chemotherapy, mucositis, and dysbiosis following intravenous broad-spectrum antimicrobial treatment. • C. difficile may be transmitted from patient to patient. What is New: • Under strict standard hygiene and contact isolation for symptomatic patients, genotyping of clinical isolates revealed that in pediatric cancer patients, CDI is not necessarily based on nosocomial transmission. • The rate of CDI-related severe complications was low.

Entities:  

Keywords:  Clostridium difficile; Clostridium difficile-associated disease; Pediatric oncology; Ribotyping

Mesh:

Year:  2017        PMID: 29273940     DOI: 10.1007/s00431-017-3070-1

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  20 in total

1.  Infection prevention and control in residential facilities for pediatric patients and their families.

Authors:  Judith A Guzman-Cottrill; Karen A Ravin; Kristina A Bryant; Danielle M Zerr; Larry Kociolek; Jane D Siegel
Journal:  Infect Control Hosp Epidemiol       Date:  2013-09-04       Impact factor: 3.254

2.  Clostridium difficile-associated disease in children with solid tumors.

Authors:  Elio Castagnola; Teresa Battaglia; Roberto Bandettini; Ilaria Caviglia; Ivana Baldelli; Marilina Nantron; Cristina Moroni; Alberto Garaventa
Journal:  Support Care Cancer       Date:  2008-09-19       Impact factor: 3.603

3.  Diagnosis and Management of Clostridium difficile Infection by Pediatric Infectious Diseases Physicians.

Authors:  Julia Shaklee Sammons; Jeffrey S Gerber; Pranita D Tamma; Thomas J Sandora; Susan E Beekmann; Philip M Polgreen; Adam L Hersh
Journal:  J Pediatric Infect Dis Soc       Date:  2013-10-17       Impact factor: 3.164

4.  Clostridium difficile infection is associated with increased risk of death and prolonged hospitalization in children.

Authors:  Julia Shaklee Sammons; Russell Localio; Rui Xiao; Susan E Coffin; Theoklis Zaoutis
Journal:  Clin Infect Dis       Date:  2013-03-26       Impact factor: 9.079

5.  Chemotherapy treatment in pediatric patients with acute myeloid leukemia receiving antimicrobial prophylaxis leads to a relative increase of colonization with potentially pathogenic bacteria in the gut.

Authors:  Michel J van Vliet; Wim J E Tissing; Catharina A J Dun; Nico E L Meessen; Willem A Kamps; Eveline S J M de Bont; Hermie J M Harmsen
Journal:  Clin Infect Dis       Date:  2009-07-15       Impact factor: 9.079

6.  Investigation of a cluster of Clostridium difficile infections in a pediatric oncology setting.

Authors:  Raymund Dantes; Erin E Epson; Samuel R Dominguez; Susan Dolan; Frank Wang; Amanda Hurst; Sarah K Parker; Helen Johnston; Kelly West; Lydia Anderson; James K Rasheed; Heather Moulton-Meissner; Judith Noble-Wang; Brandi Limbago; Elaine Dowell; Joanne M Hilden; Alice Guh; Lori A Pollack; Carolyn V Gould
Journal:  Am J Infect Control       Date:  2015-10-23       Impact factor: 2.918

7.  Novel risk factors for recurrent Clostridium difficile infection in children.

Authors:  Maribeth R Nicholson; Isaac P Thomsen; James C Slaughter; C Buddy Creech; Kathryn M Edwards
Journal:  J Pediatr Gastroenterol Nutr       Date:  2015-01       Impact factor: 2.839

8.  Epidemiology of Clostridium difficile in Germany based on a single center long-term surveillance and German-wide genotyping of recent isolates provided to the advisory laboratory for diagnostic reasons.

Authors:  Lutz von Müller; Markus Mock; Alexander Halfmann; Julia Stahlmann; Arne Simon; Mathias Herrmann
Journal:  Int J Med Microbiol       Date:  2015-08-22       Impact factor: 3.473

9.  Evaluating risk factors for Clostridium difficile infection in adult and pediatric hematopoietic cell transplant recipients.

Authors:  Nicole M Boyle; Amalia Magaret; Zach Stednick; Alex Morrison; Susan Butler-Wu; Danielle Zerr; Karin Rogers; Sara Podczervinski; Anqi Cheng; Anna Wald; Steven A Pergam
Journal:  Antimicrob Resist Infect Control       Date:  2015-10-14       Impact factor: 4.887

10.  Guideline for the management of fever and neutropenia in children with cancer and/or undergoing hematopoietic stem-cell transplantation.

Authors:  Thomas Lehrnbecher; Robert Phillips; Sarah Alexander; Frank Alvaro; Fabianne Carlesse; Brian Fisher; Hana Hakim; Maria Santolaya; Elio Castagnola; Bonnie L Davis; L Lee Dupuis; Faith Gibson; Andreas H Groll; Aditya Gaur; Ajay Gupta; Rejin Kebudi; Sérgio Petrilli; William J Steinbach; Milena Villarroel; Theoklis Zaoutis; Lillian Sung
Journal:  J Clin Oncol       Date:  2012-09-17       Impact factor: 44.544

View more
  1 in total

1. 

Authors: 
Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz       Date:  2021-02       Impact factor: 1.513

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.